Research & Literature

The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Basturk O, Yang Z, Tang LH, et al.

The American journal of surgical pathology 2015; (39(5)):683-90 doi:10.1097/PAS.0000000000000408.

Comparison of Three Ki-67 Index Quantification Methods and Clinical Significance in Pancreatic Neuroendocrine Tumors.

Kroneman TN, Voss JS, Lohse CM, et al.

Endocrine pathology 2015; (26(3)):255-62 doi:10.1007/s12022-015-9379-2.

Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.

Crippa S, Partelli S, Bassi C, et al.

Surgery 2016; (159(3)):862-71.

Metastatic pancreatic cancer presenting as linitis plastica of the stomach.

Garg S, Mulki R, Sher D

BMJ case reports 2016; (2016()).

Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.

Haugvik SP, Kaemmerer D, Gaujoux S, et al.

Current oncology reports 2016; (18(5)):28 doi:10.1007/s11912-016-0518-9.

Primary Small Cell Carcinoma of the Pancreas Presenting With Likely Paraneoplastic Features.

Caesar J, Jordan M, Kumar P, Gray C

ACG case reports journal 2016; (3(3)):190-2 doi:10.14309/crj.2016.46.

A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.

Tang LH, Basturk O, Sue JJ, Klimstra DS

The American journal of surgical pathology 2016; (40(9)):1192-202 doi:10.1097/PAS.0000000000000662.

Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial.

Maltoni M, Scarpi E, Dall'Agata M, et al.

European journal of cancer (Oxford, England : 1990) 2016; (65()):61-8.

Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.

Panagiotidis E, Alshammari A, Michopoulou S, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017; (58(1)):91-96 doi:10.2967/jnumed.116.178095.

Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial.

Temel JS, Greer JA, El-Jawahri A, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(8)):834-841 doi:10.1200/JCO.2016.70.5046.

Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.

Konukiewitz B, Schlitter AM, Jesinghaus M, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017; (30(4)):587-598 doi:10.1038/modpathol.2016.217.

Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.

Hijioka S, Hosoda W, Matsuo K, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2017; (23(16)):4625-4632 doi:10.1158/1078-0432.CCR-16-3135.

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.

Walter T, Tougeron D, Baudin E, et al.

European journal of cancer (Oxford, England : 1990) 2017; (79()):158-165 doi:10.1016/j.ejca.2017.04.009.

Early palliative care for adults with advanced cancer.

Haun MW, Estel S, Rücker G, et al.

The Cochrane database of systematic reviews 2017; (6()):CD011129 doi:10.1002/14651858.CD011129.pub2.

Liver MRI: From basic protocol to advanced techniques.

Donato H, França M, Candelária I, Caseiro-Alves F

European journal of radiology 2017; (93()):30-39 doi:10.1016/j.ejrad.2017.05.028.

Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis.

Miura F, Okamoto K, Takada T, et al.

Journal of hepato-biliary-pancreatic sciences 2018; (25(1)):31-40 doi:10.1002/jhbp.509.

Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study.

Sigel CS, Krauss Silva VW, Reid MD, et al.

Cancer cytopathology 2018; (126(1)):44-53 doi:10.1002/cncy.21934.

Clinical applicability of Tokyo guidelines 2018/2013 in diagnosis and severity evaluation of acute cholangitis and determination of a new severity model.

Gravito-Soares E, Gravito-Soares M, Gomes D, et al.

Scandinavian journal of gastroenterology 2018; (53(3)):329-334 doi:10.1080/00365521.2018.1430255.

Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study.

Sigel CS, Krauss Silva VW, Reid MD, et al.

Cancer cytopathology 2018; (126(5)):326-335 doi:10.1002/cncy.21982.

[Pancreatic Neuroendocrine Tumor Presenting as Acute Pancreatitis].

Kim M, Park JM, Lee SJ, et al.

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2018; (71(2)):98-102 doi:10.4166/kjg.2018.71.2.98.

Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma.

Ribeiro MJM, Alonso T, Gajate P, et al.

Autopsy & case reports 2018; (8(1)):e2018005 doi:10.4322/acr.2018.005.

Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3.

Konukiewitz B, Jesinghaus M, Steiger K, et al.

Human pathology 2018; (77()):70-79 doi:10.1016/j.humpath.2018.03.018.

Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances.

Guilmette JM, Nosé V

Advances in anatomic pathology 2019; (26(1)):13-30 doi:10.1097/PAP.0000000000000201.

Consolidation and prediction of long-term treatment effect of group and online mindfulness-based cognitive therapy for distressed cancer patients.

Cillessen L, Schellekens MPJ, Van de Ven MOM, et al.

Acta oncologica (Stockholm, Sweden) 2018; (57(10)):1293-1302 doi:10.1080/0284186X.2018.1479071.

Fine-Needle Aspiration-Based Grading of Pancreatic Neuroendocrine Neoplasms Using Ki-67: Is Accurate WHO Grading Possible on Cytologic Material?

Weiss VL, Kiernan C, Wright J, et al.

Journal of the American Society of Cytopathology 2018; (7(3)):154-459 doi:10.1016/j.jasc.2018.02.001.

Oncologic Emergencies: Recognition and Initial Management.

Higdon ML, Atkinson CJ, Lawrence KV

American family physician 2018; (97(11)):741-748.

Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.

Yoxtheimer LM, Heymann JJ, Cohen C, et al.

Diagnostic cytopathology 2018; (46(12)):1010-1014 doi:10.1002/dc.24088.

Communication Differences between Oncologists and Palliative Care Clinicians: A Qualitative Analysis of Early, Integrated Palliative Care in Patients with Advanced Cancer.

Thomas TH, Jackson VA, Carlson H, et al.

Journal of palliative medicine 2019; (22(1)):41-49 doi:10.1089/jpm.2018.0092.

Brain metastasis in pancreatic cancer: Two case reports.

Sasaki T, Sato T, Nakai Y, et al.

Medicine 2019; (98(4)):e14227 doi:10.1097/MD.0000000000014227.

Acute cholangitis: Diagnosis and management.

Sokal A, Sauvanet A, Fantin B, de Lastours V

Journal of visceral surgery 2019; (156(6)):515-525 doi:10.1016/j.jviscsurg.2019.05.007.

Oncologic Emergencies: The Fever With Too Few Neutrophils.

Long B, Koyfman A

The Journal of emergency medicine 2019; (57(5)):689-700 doi:10.1016/j.jemermed.2019.08.009.

High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms.

Chan DL, Bernard EJ, Schembri G, et al.

Neuroendocrinology 2020; (110(11-12)):950-958 doi:10.1159/000504673.

PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).

Sorbye H, Kong G, Grozinsky-Glasberg S

Endocrine-related cancer 2020; (27(3)):R67-R77.

Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Bellizzi AM

Human pathology 2020; (96()):8-33 doi:10.1016/j.humpath.2019.12.002.

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.

Patel SP, Othus M, Chae YK, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2020; (26(10)):2290-2296 doi:10.1158/1078-0432.CCR-19-3356.

[A Case of Small Cell Carcinoma of the Pancreas].

Sannomiya H, Okamoto T, Ryu S, et al.

Gan to kagaku ryoho. Cancer & chemotherapy 2019; (46(13)):2312-2314.

Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3.

Merola E, Falconi M, Rinke A, et al.

American journal of surgery 2020; (220(2)):284-289 doi:10.1016/j.amjsurg.2020.03.009.

Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.

Zhang P, Li J, Li J, et al.

Cancer 2020; (126 Suppl 9()):2086-2092 doi:10.1002/cncr.32750.

Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication.

Taskin OC, Clarke CN, Erkan M, et al.

Journal of gastrointestinal oncology 2020; (11(3)):548-558 doi:10.21037/jgo.2020.03.07.

Pancreatic Neuroendocrine Neoplasms: 2020 Update on Pathologic and Imaging Findings and Classification.

Khanna L, Prasad SR, Sunnapwar A, et al.

Radiographics : a review publication of the Radiological Society of North America, Inc 2020; (40(5)):1240-1262 doi:10.1148/rg.2020200025.

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.

Mosele F, Remon J, Mateo J, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2020; (31(11)):1491-1505 doi:10.1016/j.annonc.2020.07.014.

Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment.

Zhang MY, He D, Zhang S

World journal of gastrointestinal oncology 2020; (12(7)):705-718 doi:10.4251/wjgo.v12.i7.705.

A Rare Case of Locally Advanced Primary Small Cell Neuroendocrine Carcinoma of the Adrenal Gland.

Limonnik V, Shah D, Sandhu A, Monga DK

Anticancer research 2020; (40(10)):5933-5938 doi:10.21873/anticanres.14614.

Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.

Calabrò D, Argalia G, Ambrosini V

Diagnostics (Basel, Switzerland) 2020; (10(12)) doi:10.3390/diagnostics10121059.

Febrile Neutropenia: Decreasing Time to Antibiotic Administration in a Community Hospital Emergency Department.

Bruce SD

Clinical journal of oncology nursing 2021; (25(1)):23-26 doi:10.1188/21.CJON.23-26.

Grade 3 metastatic neuroendocrine neoplasms of two unusual primary sites with contrasting differentiation characteristics: Dual tracer positron emission tomography and computed tomography imaging (18F-fluorodeoxyglucose and 68Ga-DOTATATE) correlates and their treatment implications.

Loharkar S, Basu S

World journal of nuclear medicine 2021; (20(1)):125-128 doi:10.4103/wjnm.WJNM_67_20.

A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.

Patel SP, Mayerson E, Chae YK, et al.

Cancer 2021; (127(17)):3194-3201 doi:10.1002/cncr.33591.

A limited panel of INSM1 and LEF1 immunostains accurately distinguishes between pancreatic neuroendocrine tumor and solid pseudopapillary neoplasm.

Guo W, Farzaneh T, Lee W, et al.

Pathology, research and practice 2021; (223()):153462 doi:10.1016/j.prp.2021.153462.

Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Shah MH, Goldner WS, Benson AB, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(7)):839-868.

Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC).

Elzein S, Bao F, Lin R, et al.

BMC gastroenterology 2021; (21(1)):340 doi:10.1186/s12876-021-01901-7.

Successful Neoadjuvant Chemotherapy for Small-Cell Neuroendocrine Carcinoma of the Pancreas: A Case Report.

Li K, Yuan J, Li Y, et al.

Frontiers in oncology 2021; (11()):719422 doi:10.3389/fonc.2021.719422.

Radiological and Histological Correlation in Small Cell Neuroendocrine Carcinoma of the Breast: A Case Report.

Gharaibeh MM, Elobeid EA, El-Heis MA, et al.

The American journal of case reports 2021; (22()):e932274 doi:10.12659/AJCR.932274.

Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study.

Abdel-Rahman O, Koski SL

Neuroendocrinology 2022; (112(8)):777-783 doi:10.1159/000520193.

Current update on imaging for pancreatic neuroendocrine neoplasms.

Segaran N, Devine C, Wang M, Ganeshan D

World journal of clinical oncology 2021; (12(10)):897-911 doi:10.5306/wjco.v12.i10.897.

Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma.

Nakano M, Shimada Y, Matsumoto Y, et al.

Clinical journal of gastroenterology 2022; (15(2)):413-418 doi:10.1007/s12328-022-01599-4.

Effects of Early Palliative Care in Advanced Cancer Patients: A Meta-Analysis.

Shih HH, Chang HJ, Huang TW

The American journal of hospice & palliative care 2022; (39(11)):1350-1357 doi:10.1177/10499091221075570.

Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis.

Kaslow SR, Vitiello GA, Prendergast K, et al.

Annals of surgical oncology 2022; (29(6)):3522-3531 doi:10.1245/s10434-022-11477-5.

Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.

Rindi G, Mete O, Uccella S, et al.

Endocrine pathology 2022; (33(1)):115-154 doi:10.1007/s12022-022-09708-2.

Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It?

Bergerot CD, Philip EJ, Bergerot PG, et al.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2022; (42()):1-10 doi:10.1200/EDBK_100031.

Microsatellite instability in pancreatic and ampullary carcinomas: histology, molecular pathology, and clinical implications.

Luchini C, Scarpa A

Human pathology 2023; (132()):176-182 doi:10.1016/j.humpath.2022.06.009.

Volumetric parameters from [18 F]FDG PET/CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.

Langen Stokmo H, Aly M, Bowitz Lothe IM, et al.

Journal of neuroendocrinology 2022; (34(7)):e13170 doi:10.1111/jne.13170.

A rare case of metastatic pancreatic adenocarcinoma presenting as a pulmonary embolism from nonbacterial thrombotic endocarditis.

Kania B, Mekheal E, Veeraballi S, et al.

Radiology case reports 2022; (17(9)):3097-3102 doi:10.1016/j.radcr.2022.05.073.

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.

Morizane C, Machida N, Honma Y, et al.

JAMA oncology 2022; (8(10)):1447-1455 doi:10.1001/jamaoncol.2022.3395.

Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update.

Prosperi D, Gentiloni Silveri G, Panzuto F, et al.

Journal of clinical medicine 2022; (11(22)) doi:10.3390/jcm11226836.

Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.

Umetsu SE, Kakar S, Basturk O, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2023; (36(3)):100065 doi:10.1016/j.modpat.2022.100065.

Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review.

Robinson MD, Livesey D, Hubner RA, et al.

Therapeutic advances in medical oncology 2023; (15()):17588359231156870 doi:10.1177/17588359231156870.

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma.

Sorbye H, Grande E, Pavel M, et al.

Journal of neuroendocrinology 2023; (35(3)):e13249 doi:10.1111/jne.13249.

Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.

Boilève A, Faron M, Fodil-Cherif S, et al.

European journal of cancer (Oxford, England : 1990) 2023; (186()):122-132 doi:10.1016/j.ejca.2023.03.024.

Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.

Eads JR, Halfdanarson TR, Asmis T, et al.

Endocrine-related cancer 2023; (30(8)).

Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.

Raj N, Chan JA, Wang SJ, et al.

British journal of cancer 2023; (129(2)):291-300 doi:10.1038/s41416-023-02298-8.

Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study.

Imai H, Saijo K, Kawamura Y, et al.

Oncology 2024; (102(5)):359-367 doi:10.1159/000534747.

Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives.

Stumpo S, Formelli MG, Persano I, et al.

Journal of clinical medicine 2023; (12(24)) doi:10.3390/jcm12247715.

Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma.

McKinley BJ, Coston TW, Starr JS

The oncologist 2025; (30(1)) doi:10.1093/oncolo/oyae034.

Palliative Care for Patients With Cancer: ASCO Guideline Update.

Sanders JJ, Temin S, Ghoshal A, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024; (42(19)):2336-2357 doi:10.1200/JCO.24.00542.

Cognitive-behavioural therapy effectiveness for fear of cancer recurrence: systematic review and meta-analysis.

Wei F, He R, Yang X, et al.

BMJ supportive & palliative care 2024; (15(1)):1-11 doi:10.1136/spcare-2023-004639.

Incidence and survival of patients with malignant pancreatic neuroendocrine neoplasms in Germany, 2009-2021.

Stang A, Wellmann I, Holleczek B, et al.

Cancer epidemiology 2024; (93()):102659 doi:10.1016/j.canep.2024.102659.

First reported case of primary small cell cancer of the pancreas with positive TTF-1 tumor marker.

Al-Obaidi H, Moliya P, Al-Obaidi AD, et al.

Radiology case reports 2024; (19(12)):5595-5599 doi:10.1016/j.radcr.2024.08.034.

Diagnostic and prognostic biomarkers for pancreatic neuroendocrine neoplasms.

Sonnen AF, Verschuur AVD, Brosens LAA

Pathologie (Heidelberg, Germany) 2024; (45(Suppl 1)):74-82 doi:10.1007/s00292-024-01393-8.

Mixed pancreatic ductal adenocarcinoma and well-differentiated neuroendocrine tumor: A case report.

Zhao X, Bocker Edmonston T, Miick R, Joneja U

World journal of gastrointestinal oncology 2024; (16(12)):4738-4745 doi:10.4251/wjgo.v16.i12.4738.

A Unique Case of Poorly Differentiated Neuroendocrine Carcinoma With Brain and Bilateral Adrenal Metastases.

El Hajj Mouawad CJ, Kamar FG

Cancer reports (Hoboken, N.J.) 2025; (8(2)):e70130 doi:10.1002/cnr2.70130.

Successful Conversion Surgery for Locally Advanced Pancreatic Neuroendocrine Carcinoma: A Case Report.

Tohmatsu Y, Yamada M, Ohike N, et al.

Surgical case reports 2025; (11(1)) doi:10.70352/scrj.cr.24-0064.

Two Cases of Mixed Neuroendocrine Non-neuroendcrine Cell Neoplasms (MiNENs) of the Pancreas with Notable Molecular Pathological Features.

Saito S, Takayama Y, Tanaka M, et al.

Internal medicine (Tokyo, Japan) 2025; (64(23)):3372-3379 doi:10.2169/internalmedicine.5083-24.

Poorly Differentiated Neuroendocrine Tumors of the Pancreas: A Comparative Analysis of Primary Versus Secondary Tumors-A Literature Review.

Markov A, Pokhrel A, Wang JC

Biomedicines 2025; (13(6)) doi:10.3390/biomedicines13061437.

Delta-like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasms.

Thummalapalli R, Tendler S, Chou JF, et al.

medRxiv : the preprint server for health sciences 2025; doi:10.1101/2025.06.24.25330227.

Management of Neutropenic Fever in Persons with Cancer.

Doyle-Lindrud S

The Nursing clinics of North America 2025; (60(3)):479-489 doi:10.1016/j.cnur.2024.09.004.

Multifocal hemorrhagic metastases with cerebellar predominance following prolonged remission of pancreatic adenocarcinoma: illustrative case.

John D, Gomez D, Cote DJ, et al.

Journal of neurosurgery. Case lessons 2025; (10(17)).

Performance of Immunohistochemistry to Detect Rb/p53 Alterations in High-Grade Neuroendocrine Neoplasms: Staining Patterns and Comparison with Genetic Testing.

Chen R, Tihy M, Lacroix L, et al.

Endocrine pathology 2025; (36(1)):40 doi:10.1007/s12022-025-09885-w.

Case Report: Deep and durable response to talazoparib in germline BRCA2-mutated rectal neuroendocrine carcinoma.

Khealani M, Park BU, Schat R, et al.

Frontiers in oncology 2025; (15()):1705579 doi:10.3389/fonc.2025.1705579.

A potential risk factor associated with acute tumor lysis syndrome in dogs with multicentric lymphoma receiving chemotherapy.

Yamazaki H, Nagai K, Wada Y, et al.

Journal of veterinary internal medicine 2026; (40(1)) doi:10.1093/jvimsj/aalaf088.

Building a diagnostic scoring system for high-grade neuroendocrine neoplasms of the pancreas.

Kinowaki Y, Wang C, Fukumura Y, et al.

American journal of clinical pathology 2026; (165(3)) doi:10.1093/ajcp/aqaf154.

Pancreatic Neuroendocrine Tumors: From Benchside to Surgical Treatment.

Conzo G, Mongardini FM, Paolicelli M, et al.

Medicina (Kaunas, Lithuania) 2026; (62(3)) doi:10.3390/medicina62030479.

Presentation, Treatment, and Outcomes of Non-bacterial Thrombotic Endocarditis in Pancreatic Cancer: A Systematic Review.

Hussain F, Huba M, Paracha A, et al.

Cureus 2026; (18(3)):e104500 doi:10.7759/cureus.104500.

Clinical pattern and outcomes of acute cholangitis among patients at a tertiary health care facility in Kenya: a cross-sectional study.

Karani C, Odiado A, Maina N, et al.

The Pan African medical journal 2026; (53()):146 doi:10.11604/pamj.2026.53.146.52075.

Pancreatic Neuroendocrine Neoplasms.

Panda A, Itani M, Mhlanga J, et al.

Seminars in ultrasound, CT, and MR 2026; (47(3-4)):149-164 doi:10.1053/j.sult.2026.06.001.

Case Report: Primary ovarian pulmonary-type small cell neuroendocrine carcinoma mimicking benign adnexal torsion: a diagnostic challenge.

Xu S, Lv P, Li N, et al.

Frontiers in medicine 2026; (13()):1941804 doi:10.3389/fmed.2026.1941804.